Dr. Olatunji B. Alese, MD

Dr. Alese practices at Emory University Hospital Midtown in Atlanta, Georgia, part of Emory University.

Dr. Alese's NPI, 1053631010, was assigned on June 1, 2010. Dr. Alese holds Georgia license 70026.

Dr. Alese's primary practice is Emory University Hospital Midtown, at 550 Peachtree Street, NE, Atlanta, GA 30308 in Fulton County. The practice phone is (404) 686-2450.

Dr. Alese's primary practice is Emory University Hospital Midtown in Atlanta, Georgia, part of Emory University. Dr. Alese is also affiliated with Emory University Hospital. The medical group on file is Emory Clinic. Dmand AI also links Dr. Alese to 1 more hospital, 1 clinical lab, 1 home health agency, 1 ambulatory surgery center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Alese practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Alese's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Alese is licensed in Georgia.

CMS data shows 173 Medicare services from Dr. Alese across 3 procedure codes in 2024, for 84 Medicare patients. Medicare paid $12,076 for them. Every service was in an office.

CMS counts 84 Medicare patients who saw Dr. Alese in 2024. The largest group is 65 to 74, with 37 patients. 74% of them have high blood pressure, and 63% have high cholesterol. Their average risk score is 2.35, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Alese's median patient age at 70, with 53% women.

In 2024, Dr. Alese wrote 350 Medicare Part D claims for 101 patients. 66% of them were for generic drugs. CMS names the drug for 176 of them, across 9 drugs with 11 or more claims each, at $296,054 in total drug cost. In 2023, CMS named 606 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Alese for performance year 2024, reported through an alternative payment model (APM). Dr. Alese accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 87 papers to Dr. Alese, published from 2014 to 2025. 2019 was the busiest year, with 11. The most frequent topics are Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Colorectal Neoplasms. Dr. Alese has published most often in Oncologist. Dr. Alese's most frequent co-authors are Mehmet Akce, MD, Bassel Fouad El-Rayes, MD and Christina Sing-Ying Wu, MD.

Dmand AI links Dr. Alese to 11 clinical trials, 4 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Rectal Diseases, Colorectal Neoplasms and Anal Canal Carcinoma. National Cancer Institute (NCI) sponsors the most, 3. Open Payments lists research payments to Dr. Alese that name 1 trial.

CMS Open Payments shows 180 general payments to Dr. Alese from 24 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 67% of the total. Bristol-Myers Squibb Company paid the most, $24,466. It also lists 2 research payments totaling $280 from 2016 to 2017, naming 1 clinical trial.